



ImmunOs Therapeutics AG closes 2.3 Million Financing Round to Support Lead Clinical Candidate Program Acceleration

Schlieren (Zurich Area), Switzerland. – December 8, 2017 – ImmunOs Therapeutics AG, a Swiss biotechnology company leading development of a next generation innate and adaptive immunity focused immunotherapy platform for cancer, today announced the closing of its 2.3 Million CHF financing round. The proceeds of the financing will be used to advance its lead clinical candidate, a single multitasking protein agent, for treating solid tumors.

ImmunOs Therapeutics AG, spun-off of the Universities of Zurich and Basel, is developing, through extensive study of autoimmune diseases, novel immunomodulatory proteins which exhibit strong anti-tumor responses alone and in combination with market leading checkpoint inhibitors and costimulatory agonists in solid tumors. ImmunOs platform activates innate and adaptive immunity via targeting several critical, validated IO receptors with a single multitasking agent to reduce MDSCs, increase M1/M2 Macrophage ratio, activate NK cells, and expand T-Cells.

“Targeting the innate and adaptive immune system with a single multi-tasking agent represents an attractive opportunity for patients and partnerships.” said Sean R. Smith, CEO ImmunOs Therapeutics AG. “The team has made excellent progress on several of our novel proteins in the ImmunOs platform with further understanding of the relevant science and potential for treatment in solid tumors. The recently closed financing will be used to further our science, complete development milestones, and strengthen our internal capabilities.”

“This financing is an important validation of ImmunOs science and to accelerate development of our lead clinical candidate. Furthermore, the team continues to develop additional unique ImmunOs multi-tasking agents with strong anti-tumor properties and with potential to enter clinic. As the science continues to evolve, the validation of our products shows promising results for successful translation into clinic to treat patients with serious disease” said Dr. Osiris Marroquin-Belaunzaran, Chief Scientific Officer at ImmunOs Therapeutics AG.

About ImmunOs Therapeutics AG:

ImmunOs Therapeutics AG is a biotechnology company focused on discovering and developing the next generation of novel human immunomodulatory proteins focused in innate and adaptive immunity. Our mission is to develop novel therapeutics that will improve the lives of patients with serious disease.

ImmunOs Therapeutics AG lead program is a next generation, novel platform of biologics that differ from the common competitor antibodies as they target diverse immunoregulatory receptors using one molecule to create a synergistic response between immune cells that activate anti-tumor responses

built upon years of research and development. ImmunOs Proteins work directly on the Innate Immune System (MDSCs, Macrophages and NK Cells) and Indirectly on the Adaptive Immune System by allowing the expansion of T cells through the inhibition of MDSC cells, leading to a strong anti-tumor response in combination with checkpoint inhibitors (CTLA-4, PD-1, PD-L1) and costimulatory agonists (e.g. 4-1BB) in multiple cancer indications. For more information, please visit www.immunotherapeutics.com.



Contact:

Investor Relations

Wagistrasse 14

8952 Schlieren (Zurich Area)

info@immunotherapeutics.com